Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

Allergy Therapeutics (AGY)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

7.85p

Change Today:

-0.15p
52 Week High: 8.00
52 Week Low: 3.88

Currency: UK Pounds
Shares Issued: 4,766.44m
Volume: 13,198

Market Cap: £374.17m
RiskGrade: 268

Trade now with Barclays Stockbrokers

Update - Allergy Therapeutics is a top faller in its sector - can you take advantage with spread betting? Find out more

AGY Overview

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. Our vaccines are aluminium free. Driving convenience; our ultra-short course treatments make life easier and increase adherence.

1 Day Chart

6 Month Chart

More Allergy Therapeutics charts

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

	Latest	F'cast
Div Yield	0.0%	0.0%
Div Cover	n/a	n/a
Op Mrgn	-63.9%	-41.9%
ROCE	n/a

	Latest	F'cast
P/E	n/a	n/a
PEG	n/a	n/a
Pr/Revenue	6.9	5.6
Pr/Book	102.8

	Latest	F'cast
Revenue	-7.4%	5.1%
PBT	n/a	n/a
EPS	n/a	n/a
DPS	n/a	n/a

AGY Fundamentals

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Jun-20	78.20	8.07	1.11p	12.6	0.1	+102%	n/a	0.0%
30-Jun-21	84.33	3.66	0.45p	55.6	n/a	-60%	n/a	0.0%
30-Jun-22	72.77	(12.66)	(2.14)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-23	59.59	(41.77)	(6.43)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-24	55.20	(39.17)	(1.07)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AGY Forecasts

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Jun-25	58.00	(24.30)	(0.76)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-26	77.00	(13.50)	(0.50)p	n/a	n/a	n/a	n/a	0.0%

Allergy Therapeutics forecasts

AGY Company Announcements

Interim Results for six months ended 31 Dec 2024	31-Mar-2025	07:00	RNS
Advancement to final phase of PROTECT trial	27-Mar-2025	07:00	RNS
New Executive Long Term Incentive Awards	03-Mar-2025	07:00	RNS

More Allergy Therapeutics agy company announcements

AGY ShareCast News

Allergy Therapeutics starts dosing peanut allerg...	27-Mar-2023	ShareCast
Allergy Therapeutics confident in funding as res...	20-Jan-2023	ShareCast
Allergy Therapeutics pauses production at Freema...	04-Oct-2022	ShareCast

More Allergy Therapeutics ShareCast news

AGY Top Newspaper Links

Allergy drug firm hit by trials setback	12-Jul-2007	The Independent
Need to Know: Global Business Briefing	25-Mar-2006	Times

Latest AGY Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

AGY Market Data

Currency	UK Pounds
Share Price	7.85p
Change Today	-0.15p
% Change	-1.88 %
52 Week High	8.00
52 Week Low	3.88
Volume	13,198
Shares Issued	4,766.44m
Market Cap	£374.17m
RiskGrade	268